Executive Management

Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the National Academy of Medicine. We believe Dr. Dybul’s extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.

Luisa Puche, has served as a senior accounting and financial advisor and president of Puche Group, LLC, since 2015. She has served in a variety of advisory capacities for both public and private organizations, such as technical accounting consultations; complex technical implementations, M&A transactions; IT Risk assessments; and SOX 404 implementations. Leveraging her broad global audit, advisory, and corporate expertise, Luisa has provided strong cross-functional leadership experience managing small and large projects for both publicly-traded and privately-held companies in various industries including a global implementation of the latest revenue recognition accounting standard for Del Monte, a $4B publicly traded global fresh produce company, as well as the global implementation of their SOX-404 program.

Previously, Luisa served in various senior executive roles at Brightstar Corp., a $10B global wireless device services provider, with public reporting requirements, including as Vice President and Global Controller and Interim Chief Accounting Officer. During her tenure at the Company she was responsible for the financial reporting of 55 countries, as well as instrumental in various key transactions including an $1.6B European acquisition and the sale of Brightstar to SoftBank. Luisa was also an executive at Ernst & Young, a big 4 accounting firm, where she worked for 10 years.

Highlights of her public company clients include: Del Monte Fresh Produce Company, Royal Palm Venture Capital, Terremark Worldwide, Knight-Ridder, Inc. and Vanguard Car Rental, Inc. (formerly Alamo and National Car Rental).
Luisa holds a Bachelor’s of Accounting from Florida International University. The above qualifies Luisa Puche to serve as CFO.

François Binette, joined Enochian Biosciences as Executive Vice President for Research and Development, bringing over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. Dr. Binette’s broad industry experience spans a wide range of serious medical condition, from orthopedics to ophthalmology, CNS, and immuno-oncology, driving cutting edge innovation from bench top to bedside. During his first industry appointment at Genzyme Tissue Repair in Cambridge, he helped pioneer Carticel™ for cartilage repair, the first FDA BLA-approved cell therapy product for human use. He then led R&D for Biosyntech, a startup biomaterials company in Montreal applying its proprietary platform for various tissue engineering and drug delivery applications. Dr. Binette then joined the DePuy Franchise of Johnson and Johnson (JNJ), the second largest orthopedic business worldwide where he led several innovative regenerative medicine combination product development initiatives from discovery to approved clinical trials in US and Europe. Following JNJ, Dr. Binette joined the Spinal and Biologics business unit of Medtronic, the world’s largest medical device company, developing biologics, active devices, and combination products for interventional spine procedures for back pain. More recently as part of the Lineage Cell Therapeutics executive leadership team, Dr. Binette led the CNS franchise as well as general pipeline development, contributing to one of the largest non-cancer cell therapy corporate partnership deals with Genentech worth over $650 million in upfront and milestone payments. He received his PhD from Laval University in Québec City, followed with post-doctoral training at the Sanford-Burnham institute in La Jolla, and Harvard Medical School in Boston.

Greg Duczynski joins us as Senior Vice President for Clinical Operations after a distinguished 32-year career of experience with Pfizer. Since 2016, he served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader. During his tenure at Pfizer his positions ranged across a broad array of clinical operations functional areas. During the most recent years he has focused his time bringing a novel Gene Therapy program for Duchenne Muscular Dystrophy into the clinic and successfully leading the program into global Phase III Trials. Prior to that Greg built and managed teams and large groups of colleagues and contractors in clinical project management, study management, clinical project planning, data management and statistical programming. During that time, he contributed to and lead various resourcing initiatives focused upon implementing functional service provider and referred clinical research organization resource models. In that capacity Greg initiated and established long term ongoing relationships with external resource providers.

Early in his career he pioneered electronic data capture processes by partnering with emerging central laboratory partners and the first generation of investigator site CRF remote data capture technologies.

However, working directly in clinical operations and helping design new studies and clinical programs and then leading them through the full clinical development program lifecycle remains his first passion.

Dr. Lu Chen has more than a decade of research & development and product development experience in the Cell and Gene Therapy space. She received her Ph.D. in Biomedical Sciences from Albert Einstein College of Medicine (Bronx, New York) in 2009. Prior to joining Enochian BioSciences, Lu filled various scientific and leadership roles in the biotechnology and pharmaceutical industries. She worked at Atara Biotherapeutics as a Principal Scientist in the Process Sciences group and led the effort to develop a scale-up allogenic T cell manufacture platform for treating cancer and autoimmune diseases. As a Sr. Scientist at FUJIFILM Irvine Scientific, she led the Cell-based Technology team for Cell and Gene Therapy product development. At Caladrius Biosciences, she was a Scientist and led the MOA study of a dendritic cell vaccine for melanoma treatment in a Phase III clinical trial. She also served as a post-doctoral fellow and project scientist at the University of California Irvine. She received multiple fellowship awards from the California Institute of Regenerative Medicine (CIRM) and National Institutes of Health (NIH) as a post-doctoral fellow and a graduate student. Her significant work in both industry and academia has resulted in the development of several commercial products used in cell and gene therapy and publications in top peer-reviewed journals.